Press

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents

Jul 28 • 2 min read

Revive Therapeutics Ltd. (OTCQB: RVVTF / CSE: RVV / FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has filed a provisional patent application titled “Compositions, methods and uses of Bucillamine in the treatment of a victim exposed to a…

Mind Cure Announces LNG Energy Group Credit Agreement in the Amount of U.S. $70 Million to Acquire Lewis Energy Colombia, Inc.

Jul 28 • 2 min read

Mind Cure Health Inc. (CSE: MCUR / OTC: MCURF) is pleased to announce that a wholly-owned subsidiary of LNG Holdings Inc. (formerly known as LNG Energy Group Inc.) (“LNG Energy“) has entered into a definitive credit agreement (the “Credit Agreement“) with Macquarie Group (the “Lender“) in the aggregate principal amount of U.S.$70 million in order to complete…

Optimi Health Announces Receipt of Purported Termination Notice

Jul 28 • 2 min read

Optimi Health Corp. (CSE: OPTI / OTCQX: OPTHF / FRA: 8BN) has received a termination notice and demand for payment pursuant to a definitive supply agreement (the “Supply Agreement”) with a private entity focused on developing mushroom-based therapeutics. For further details of the Supply Agreement, see the Company’s press release dated May 4, 2023, a…

Small Pharma Reports Fiscal First Quarter 2024 Highlights

Jul 28 • 5 min read

Small Pharma Inc. (TSXV: DMT / OTCQB: DMTTF), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, has today published its financial results for the fiscal first quarter ended May 31, 2023. A complete copy of the results and the corresponding management’s discussion and analysis can be found under the Company’s profile…

Mydecine Innovations Group Provides Corporate Update

Jul 25 • 2 min read

Mydecine Innovations Group Inc. (NEO:MYCO / OTC:MYCOF / FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that John Ross, the Company’s current Chief Financial Officer has been appointed as Corporate Secretary, effective immediately….

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435